| Current
Pharmaceutical Design
ISSN: 1381-6128 - Volume 14, 36 Issues, 2008
Instructions for Authors
MANUSCRIPTS SUBMISSION: Authors wishing to submit comprehensive
reviews in any frontier area of drug design should contact
the Executive Guest Editor of the relevant field with the
title and a one page summary of the proposed contents. A copy
of the summary proposal should also be sent to the Journal
Editor-in-Chief. Should authors wish to submit a review article
in any other area of drug design not stated below, then please
first submit a summary proposal to the Editor-in-Chief,
Prof. William A. Banks, GRECC, Veterans Affairs Medical
Center-St. Louis & Saint Louis University School of Medicine,
Division of Geriatrics, Department of internal medicine, 915
North Grand Blvd., St. Louis, MO 63106, USA Fax: +1 314-289-6734;
e-mail :bankswa@slu.edu
Each first named author who publishes an article will receive
a free one year subscription to the journal (of the current
volume). The Executive Editors for the various fields are
as follows: Cardiovascular and Hematological Agents.
Ho-Sam Ahn, (USA), e-mail: ho-sam.ahn@spcorp.com
Cardiovascular and Hematological Agents. Johann Wolfgang
Auer, (Austria), e-mail: johann.auer@khwels.at
COX 2 Inhibitors. Angel Lanas Arbeloa (Spain),
analas@doymanet.es
CNS Agents: Masato Asanuma, (Japan), e-mail:
asachan@cc.okayama-u-ac.jp
Anti-Infective Agents: Mitchell A. Avery/Vassil St.
Georgiev, (USA), e-mail: vg8q@nih.gov
The Blood Brain Barrier in Health & Disease: William
A. Banks, (USA), e-mail: bankswa@slu.edu
Genomics and the Prospects of Antibacterial &
Antifungal Agents: John F. Barrett, (USA), e-mail:
john.barrett@bms.com
Anti-Infective Agents: Fatima Z. Basha/Les Mitscher,
(USA), e-mail: fatima.z.basha@abbott.com
Anti-Cancer Drugs: E.S. Bergmann-Leitner, (USA),
e-mail: esbl@helix.nih.gov
Peptide Radiopharmaceuticals: Jay Elliot Blum, (USA),
e-mail: peptidedoc@cox.net
Anti-Angiogenesis Agents: Maurizio Botta,
(Italy), e-mail: manettif@unisi.it
Development of Cytokines for Use in Treatment of Blood
Disorders: Ken Bradstock, (Australia), e-mail: Bradstok@icpmr.wsahs.nsw.gov.au
COX-II Inhibitors: Peter Brooks, (Australia),
e-mail: lineman@mailbox.uq.edu.au
Kinase and Phosphatase Drug Discovery and Design.
Dirksen Bussiere, (USA), e-mail:
Dirksen_Bussiere@chiron.com Anti-Cancer Agents:
Giovanni Capranico, (Italy), e-mail: giovanni.capranico@unibo.it
Anti-Inflammatory and Antiallergy Agent: Tz-Chong
Chou, (Taiwan), e-mail: tcchou@ms5.hinet.net
Enzyme / Protease Inhibitors: Nestor Omar Concha,
(USA), e-mail: Nestor_O_Concha@gsk.com
Radiolabelled Compounds for Drug Discovery and Development:
G.J.R. Cook, (UK), e-mail: gary.j.cook@kcl.ac.uk
Anti-Thrombotics. Dermot Cox, (Ireland),
e-mail: dcox@rcsi.ie Cell
Biology and Chemotherapy of Trypanosomiasis and Leishmaniasis:
Wanderley de Souza, (Brazil), e-mail: wsouza@sect.rj.gov.br
Death Receptor Ligands: E.G. Elisabeth de Vries,
(The Netherlands), e-mail: e.g.e.de.vries@int.azg.nl
Antimetabolite Agents: Galal Hamza Elgemeie,
(Egypt): e-mail: rughe@rusys.eg.net
Neuropeptide-based Drug Design: Illana Gozes, (Israel),
e-mail: igozes@post.tau.ac.il
Analgesic Drug Design and Discovery: Gurmit Grewal,
(USA), e-mail: Gurmit.Grewal@ucb-group.com
Pharmacophore Elucidation & Their Use in Drug
Design. Salvatore Guccione, (Italy), e-mail: guccione@mbox.unict.it
Nitric Oxide in Drug Design & Discovery: D. Hadjipavolou-Litina,
(Greece), e-mail:
hadjipav@pharm.auth.gr Recent Therapeutic Approaches
to the Treatment of cognitive Impairment and Dementia: Bernd
Ibach (Germany), e-mail: andrea.pielmeier@klinik.uni-regensburg.de
Cardiovascular and Hematological Agents. Makoto Katoh,
(Japan), e-mail: katoh-m@tanabe.co.jp
Anti-Inflammatory and Anti-Allergy Agents: Milton
John Kiefel, (Australia), e-mail: m.kiefel@mailbox.gu.edu.au
Radiopharmaceuticals in Drug Discovery and Development:
Michael Kassiou (Australia), e-mail: mkassiou@med.usyd.edu.au
Anti-Cancer Agents: Alan P. Kozikowski / Maurizio
Pellecchia (USA / USA), e-mail: kozikowa@uic.edu
/ e-mail: mpellecchia@burnham.org
Ion Channels as a Target for Drug Design: Kwok-Keung Tai
(USA) kktai@yahoo.com Antihypertensive
Drugs: Gregory Y.H. Lip, (UK) e-mail: G.Y.H.Lip@bham.ac.uk
Cardiovascular and Hematological Agents. Eva Lonn,
(Canada), e-mail: eva@ccc.mcmaster.ca
Allergy-Asthma: Jan Lotvall, (Sweden), e-mail: jan.lotvall@hjl.qu.se
Infectious Disease-Drug Delivery to Treat: Shigefumi
Maesaki (Japan), e-mail: maesaki@saitama-med.ac.jp
Angiogenesis Agents: Cezary Marcinkiewicz, (USA),
e-mail: cmarcink@nimbus.ocis.temple.edu
Protease Inhibitors: Robert W. Marquis, (USA),
e-mail: Robert_W_Marquis@sbphrd.com
Update in the Medical Treatment of Head Injured Patients
in Relation to Outcome: Maria Mataro/J. Sahquillo (Spain),
e-mail: mmataro@terra.es
Antithrombotic Drug Design. Hiroyuki Matsuno,
(Japan), e-mail: leuven@cc.gifu-u.ac.jp
Applications of ACE Inhibitors and A2 Receptor Blockers:
Agostino Molteni, (USA), e-mail: moltenia@umkc.edu
Antihypertensive: Trefor Morgan, (Australia),
e-mail: t.morgan@physiology.unimelb.edu.au
Osteoporosis: Paul Morley, (Canada), e-mail:
paul.morley@nrc.ca
Purine Receptors as Targets for Future Drugs: Christa
E. Mueller, (Germany), e-mail: christa.mueller@uni-bonn.de
Anti-Cancer Agents: I. Niculescu-Duvaz, (UK),
e-mail: ion@icr.ac.uk Protease
Inhibitors: Vicki L. Nienaber, (USA), e-mail: vicki.nienaber@corvas.com
Cytokines and Anti-cytokines: Atsushi Oda,
(Japan), e-mail: aoda@med.hokudai.ac.jp
DNA Topoisomerases as Targets for Anticancer Drugs:
Neil Osheroff, (USA), e-mail: osheron@ctrvax.vanderbilt.edu
HIV Drug Design (Anti-HIV Agents): Keykavous Parang,
(USA), e-mail: kayparang@hotmail.com
Tumour Selective Drug Activation: Laurence H. Patterson,
(UK), e-mail: medchem@ulsop.ac.uk
Bactericidal Peptides: Antonio Pellegrini,
(Switzerland), e-mail: pellegrinia@access.unizh.ch
Drugs in Interventional Cardiology: Peter W. Radke,
(Germany), e-mail: PRadke@ukaachen.de
Transplantation-Anti-Rejection Agents. Markus Richter,
(Germany), e-mail: drrichter@gmx.net
Obesity Drug Design (Anti-Obesity Agents): J.C. Russell,
(Canada), e-mail: Jim.Russell@ualberta.ca
Cancer Vaccine and Immunotherapy: Farid Saleh,
(Kuwait), e-mail: fred@hsc.edu.kw
Enzyme Inhibition: Michel Salzet, (France),
e-mail: michel.salzet@univ-lille1.fr
Cytokines: Computer Aided Design of Proteins for Therapeutic
Use: Catherine H. Schein, (USA), e-mail: chschein@utmb.edu
G Protein-Coupled Receptor Drug Targets. Patrick Sexton,
(Australia), e-mail: p.sexton@hfi.unimelb.EDU.AU
Glutamate Receptor: Sandor Solyom (Hungary),
e-mail: h13759sol@helka.iif.hu
Protein MIisfolding Disorders: Claudio Soto
(Switzerland) e-mail: claudio.Soto@serono.com
Autoimmune Diseases: D. Stahl, (Germany),
e-mail: stahld@uni-muenster.de
Peptides and Peptidomimetics as Anti-cancer Therapeutics
as Anti-Cancer Therapeutics: Nadya Tarasova, (USA),
e-mail: tarasova@ncifcrf.gov
Recent Advances in Developmental Toxicology: Gian
Mario Tiboni (Italy), e-mail: tiboni@phobos.unich.it
Regulatory Peptides: Nese Tuncel (Turkey),
e-mail: ntuncel@ogu.edu.tr
PET and SPECT in Drug Design: Aren van Waarde, (The
Netherlands), e-mail: aren@pet.azg.nl
Endocrine & Metabolic Agents: Allan Wagman, (USA),
e-mail: allan_wagman@chiron.com
Antihypertensive Agents: Jiguang Wang, (Belgium),
e-mail: Jiguang.Wang@med.kuleuven.ac.be
Obesity Drug Design: Christian Weyer, (USA),
e-mail: cweyer@amylin.com
Central Nervous System Agents: Joseph Yevich/David
W. Smith, (USA), e-mail: yevichj@bms.com,
e-mail: smithdw@bms.com
Recent Advances in Antiviral Agents Shin-Ru Shih (Taiwan),
e-mail: srshih@mail.cgu.edu.tw
Computational biology and drug design Xiaoqin Huang
(USA), e-mail: xhuan5@email.uky.edu,
Antidepressant Drug Design Lee E. Schechter,
email: schechl@wyeth.com,
HIV Entry Inhibitors Shibo Jiang, email:
sjiang@nybloodcenter.org
, Direct Thrombin Inhibitors and Synthetic F Xa Inhibition,
Giuseppe G. Nenci, e-mail: medvasc@unipg.it
Spinal Cord Injury and Repair Weihong Pan (USA),
email: weihong.pan@pbrc.edu
Manuscript Preparation: The manuscript should be approximately
up to 50 pages in length for full-length reviews and 30 pages
for a mini-review, All pages should be numbered. Abbreviations
should be defined the first time that they are used in the
manuscript and a list of abbreviations used should be provided.
Spelling may be in British or American but a mixture is not
acceptable.
The manuscript, written in English, should be typed in double
spacing throughout on A-4 or American quarto paper. Dot matrix
print or any print that is difficult to read is unacceptable.
Two copies of the manuscript must accompany the original (along
with a computer disk) and should be sent to the Editor at
his address. Abbreviations used should be provided. Please
provide your telephone and fax numbers along with your e-mail
address with all submissions to the Guest Editor.
Manuscript Organization: The manuscript should be
divided as: Title page, abstract and the main text. The text
may be subdivided further according to the areas to be discussed.
This should be followed by the Acknowledgement (if any) and
Reference sections. The first page should contain the title,
the authors names (initials and surname only), with an asterisk
in front of the name of the principal author.
Conflict of Interest: Financial contributions
to the work being reported should be clearly acknowledged,
as should any potential conflict of interest.
Abstract: The abstract should not exceed 250 words
and it should condense the essential features of the review
article, with the focus on the major advances in the field.
Key Words: Authors must supply up to eight key words
along with their manuscript.
Text: The main text should begin on a separate page
and it may be subdivided into separate sections. The review
article should mention any previous important reviews in the
field and contain a comprehensive discussion starting with
the general background of the field. It should then go on
to discuss the salient features of recent developments. The
authors should avoid presenting material, which has already
been published in a previous review. The reference numbers
should be given in square brackets in the text. Acknowledgements
should be kept to a minimum.
Tables:
- Data Tables should
be submitted in Microsoft Excel or in Microsoft Word table
format.
- Each table should include
a title/caption explaining what the table shows. Detailed
legends may then follow.
- Tables should be given
on separate pages with indications on the left hand margin
to the text, as to the appropriate placement of the tables.
- Tables should not contain
vertical rules.
- Columns and rows of
data should be made visibly distinct by ensuring the borders
of each cell display as black lines.
- Tables should be numbered
consecutively in order of their citation in the body of
the text, with Arabic numerals.
- If a reference is cited
in both the table and text, insert a lettered footnote in
the table to refer to the numbered reference in the text.
- Tabular data provided
as additional files can be submitted as an Excel spreadsheet.
Figures
/ Illustrations:
All authors must strictly follow the guidelines below for
preparing illustrations for publication in Current
Pharmaceutical Design.
Editorial
Requirements:
The quality of the illustrations printed in the journal largely
depends on the quality of the figures/illustration provided
by the author. In preparing artwork or graphics for publication,
keep in mind the following points.
- Submit the original artwork or a photographic
print of the original for publication.
- Do not submit photocopies. (Hardcopy submission
requirement)
- Illustrations should be provided as separate
files, not embedded in the text. (Hardcopy submission requirement)
- Remove all color from graphics except for
those illustrations (Greyscale), which are intended to be
printed in color.
- Good quality of hardcopy originals are a
requirement.
- Figures should be referred to as “Fig.
(1)”, “Fig. (2)” etc. in the
text with figure numbers in bold within round bracket.
- Revised manuscripts should contain a complete
set of artwork and photographs.
Technical
Details:
- Figures should be provided on high quality,
white, smooth opaque paper. (Hardcopy requirement)
Format
& Resolution:
- The following file formats can be accepted.
(Preference in order of appearance) : PDF, TIFF, JPEG, GIF
- Illustrations must fit a single or double
column format on the journal page, according to the following
guideline below:
|
HEIGHT | WIDTH |
SINGLE COLUMN |
24 cm (max) |
8.5 cm (max) | DOUBLE
COLUMN | 24
cm (max) | 18
cm (max) |
- Whenever possible, submit graphics that do
not have to be reduced to fit the standard figure size.
- Use the best resolution available (hardcopy
submission requirement). For online submission the maximum
resolution is 300 dpi.
- Avoid textures and shadings giving a three-dimensional
effect to the illustration.
- Symbols and lettering in the illustration
should be of similar size.
- Smaller lettering is used.
- Font: Times New Roman or Helvetica is preferable.
Font size: 10pt (maximum)
- Line drawings should have clear and sharp
lines and should be of uniform density. Moreover, lines
should be continuous without any breaks.
- Do not use lines thinner than 1 point.
Color Figures / Illustrations:
Photographs:
Submit high-contrast prints that are of single- or double-column
width so that they will not have to be reduced when printed.
Negatives are not acceptable. However, in case of hardcopy
submission, color illustrations and plates can be published
from 35 mm color slides.
Chemical Structures: Chemical structures must be prepared
according to the guidelines below.
Structures should be prepared using a suitable drawing program
e.g. ChemDraw and provided as separate file, submitted both
on disk and in printed formats.
Numbers in bold should identify all chemical structure. If
a name is also used to describe the compound, the associated
number if required, should be in bold in parenthesis, e.g.
"compound (1)".
Structure
Drawing Preferences: [As according to the ACS style sheet] Drawing
Settings:
Chain angle 120°
Bond spacing 18% of width
Fixed length 14.4 pt (0.500cm,
0.2in)
Bold width
2.0 pt (0.071cm, 0.0278in)
Line width
0.6 pt (0.021cm, 0.0084in)
Margin width 1.6 pt (0.096cm)
Harsh spacing 2.5 pt (0.088cm, 0.0347in)
Text
settings:
Font Times
New Roman / Helvetica
Size
8pt
Under
the Preference Choose:
Units
points
Tolerances 3
pixels
Under Page Setup Use:
Paper US
letter
Scale
100%
Reference: References
should be numbered sequentially in square brackets [ ] in
the text and listed in the same numerical order in the reference
section.
All references must be complete and accurate. Online citations
should include date of access. Journal titles should conform
to the present Index Medicus abbreviations. It is necessary
to list all authors if the total number of authors is 6 or
less and for more than six authors use et al. References should
be listed in the following Vancouver style:
Typical Paper Reference:
Boehm M, Nabel EG. Angiotensin-converting enzyme 2--a new
cardiac regulator. N Engl J Med 2002; 347: 1795-7.
SoRelle R. Long reach of the N-terminal of B-type natriuretic
peptide. Circulation 2002; 106: 9059-63.
Typical Chapter Reference:
Stevenson WG, Friedman PL. In: Hennekens CH Ed, Clinical trials in cardiovascular
disease. Philadelphia, WB Saunders Co. 1999; 217-30
Abstracts, unpublished data and personal communications (which
can only be included if prior permission has been obtained)
should not be given in the references section but they may
be mentioned in the text and details provided as footnotes.
Manuscript Submission: Two copies of the manuscript
must accompany the original along with the soft copy of the
manuscript on a computer floppy disk(s) in MS Word file format
(or created in any other well-known word processing software)
should be submitted. To achieve rapid publication authors
are encouraged to e-mail or fax their submission to the appropriate
editorial office (see above) at the same time that they mail
the manuscript. For even faster publication, authors are encouraged
to submit their entire manuscript via BenthamÆs online
submission service (see below). Authors must provide their
full address, telephone and Fax numbers with E-Mail address
with all submissions.
For expedient and speedy reviewing of author's manuscripts,
authors are strongly advised to include the PDF file of their
manuscript on a floppy or zip disk, into the mailing material.
At the same time the package is mailed, please also send by
e-mail a copy of the PDF file of the manuscript to the editorial
office.
Online Manuscript Submission: (preferable)
To facilitate speedy and cost-effective submission of abstracts
and manuscripts, an online submission and tracking service
via Internet is being offered. Once the Editor-in-Chief of
the journal has accepted your abstract, we would prefer that
you submit your full manuscript online via our online submission
service available at www.bentham-mps.org
or by FTP submission at www.bentham-ftp.org
For online submission, please provide your complete manuscript
in the form of a single zipped folder containing
all the material (main text, figures/ illustrations, scanned
photographs, tables, chemical structures drawn in ChemDraw)
as separate files and a PDF version
of the entire manuscript with all the figures/ illustrations
/ tables / chemical structures etc., embedded in the text
exactly in the manner as they should appear in printing.
Authors are required to proofread the PDF version of their
manuscript before submission. The article will be published
exactly as received and the Publishers will not be responsible
for any error occurring in the manuscript in this regard.
You may, however, still submit your abstracts and manuscripts
through conventional surface mail.
A successful electronic submission of a manuscript will be
followed by a system-generated acknowledgement to the principal/corresponding
author within 72 hours of the dispatch of the manuscript.
Any queries therein should be addressed to mahmood@bentham.org
and copied to Jalil@bentham.org
Page Charges: No page charges will be levied to authors.
Language Editing: Manuscripts submitted containing
many English typographical errors will not be published. Authors
from non-English language countries are advised to use the
services of our professional language editing department prior
to submitting their manuscript to the Journal. Please contact
Bentham Publishing Services www.benthampublishingservices.com
for a language editing quote at e-mail: info@benthampublishingservices.com
stating the total number of words of the article to be edited.
Proofs: Authors are sent page proofs. To
avoid delays in publication, proofs should be checked immediately
for typographical errors and returned within 48 hours. Authors
will be charged for excessive changes made at the page proof
stage.
Reprints: Each first named author will receive
by e-mail a free copy of their article as a PDF file. The
PDF file is a watermarked version of the published article
which is exclusively for the author's own use and may not
be copied or distributed. Reprints may be ordered from the
Publisher prior to publication of the article. First named
authors may also order a personal print and online subscription
of the journal at 50% off the normal subscription rate by
contacting the subscription department at e-mail: subscriptions@bentham.org
Bentham Open Access: Accepted articles can
be published online for free open access for all to view.
Open access publishing provides the maximum dissemination
of the article to the largest audience. Authors must pay for
this service. All corresponding authors will be asked to indicate
whether or not they wish to pay to have their paper made freely
available on publication. If authors do not select the Open
Access option, then their article will be published with standard
subscription-based access at no charge. Open access articles
are published under the terms of the Creative Commons Attribution
Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)
which permits unrestricted, non-commercial use, distribution
and reproduction in any medium, provide the work is properly
cited.
Bentham Science offers authors the choice of open access publication
of their articles at a fee of US$ 2,800 per published article
which allows indefinite online publication with BOTH Bentham
Science, PubMed Central and UK PubMed Central. For more information
please contact us at e-mail: openaccess@bentham.org
Reviewing and Promptness of Publication:
All papers submitted for publication will be immediately subjected
to editorial scrutiny, usually in consultation with members
of the Editorial Advisory Board. Every effort will be made
to assess the papers quickly. The papers will be typeset and
the proofs dispatched to the authors normally within 4 weeks
of their acceptance.
Copyright: It is a condition of publication
that manuscripts submitted to this journal have not been published
and will not be simultaneously submitted or published elsewhere.
Plagiarism is strictly forbidden, and by submitting the article
for publication the authors agree that the publishers have
the legal right to take appropriate action against the authors,
if plagiarism is discovered. By submitting a manuscript the
authors agree that the copyright of their article is transferred
to the publishers if and when the article is accepted for
publication.
|
